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Abstract
Background:  The objective of this study was to identify the molecular processes
responsible for the anti-lesional activity of imiquimod in subjects with actinic keratosis using
global gene expression profiling.
Methods:  A double-blind, placebo-controlled, randomized study was conducted to
evaluate gene expression changes in actinic keratosis treated with imiquimod 5% cream.
Male subjects (N = 17) with ≥ 5 actinic keratosis on the scalp applied placebo cream or
imiquimod 3 times a week on nonconsecutive days for 4 weeks. To elucidate the molecular
processes involved in actinic keratosis lesion regression by imiquimod, gene expression
analysis using oligonucleotide arrays and real time reverse transcriptase polymerase chain
reaction were performed on shave biopsies of lesions taken before and after treatment.
Results: Imiquimod modulated the expression of a large number of genes important in both
the innate and adaptive immune response, including increased expression of interferon-
inducible genes with known antiviral, anti-proliferative and immune modulatory activity, as
well as various Toll-like receptors. In addition, imiquimod increased the expression of genes
associated with activation of macrophages, dendritic cells, cytotoxic T cells, and natural
killer cells, as well as activation of apoptotic pathways.
Conclusion: Data suggest that topical application of imiquimod stimulates cells in the skin
to secrete cytokines and chemokines that lead to inflammatory cell influx into the lesions
and subsequent apoptotic and immune cell-mediated destruction of lesions.
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Background
Actinic keratosis (AK) are common, cutaneous, precancer-
ous neoplasms appearing as rough, dry, scaly lesions that
occur primarily on the sun-exposed skin of middle-aged
and elderly people [1-3]. Although the exact mechanism
of pathogenesis of AK development is unknown, part of
the pathogenesis may involve suppression of the immune
response against dysplastic cells [4]. It is believed that pro-
longed ultraviolet exposure changes the immune surveil-
lance mechanism of the skin, contributing to the
tolerance of tumor cells [5]. If left untreated, AK can
progress to squamous cell carcinoma, a locally aggressive
and occasionally metastatic tumor type [6]. Standard
treatment of AK includes various types of surgical and
chemical treatments [7,8], which are often associated with
scarring and infection, and may not address sub clinical
lesions [8].
Toll-like receptors (TLR) are pattern recognition receptors
that detect pathogen-associated molecular patterns
(PAMPs) and play key roles in the activation of innate and
adaptive immune responses [9,10]. Currently, 10 human
TLRs have been identified. The natural ligands for all but
TLR10 have also been identified [9]. Toll-like receptors are
primarily expressed on immune cells such as monocytes,
dendritic cells (DCs), and lymphocytes [11], but some
TLRs are also expressed on nonimmune cells, including
endothelial cells, epithelial cells, and keratinocytes [12].
The role of TLRs in the pathogenesis and treatment of der-
matological diseases is increasingly recognized [13]. Imi-
quimod, a member of a class of drugs termed immune
response modifiers has been shown to be a selective TLR7
agonist [[14,15], and unpublished internal data]. Imiqui-
mod is the first TLR-agonist pharmaceutical product
approved for human use, and is indicated for the topical
treatment of external genital and perianal warts caused by
human papilloma virus [16]. Recently, the approved indi-
cations have been expanded to include treatment of AK
[17] and superficial basal cell carcinoma [18-20].
The antiviral and anti-tumor activity of imiquimod is
believed to be due to the activation of the innate immune
response, specifically activation of antigen-presenting
cells such as monocytes, macrophages and plasmacytoid
and myeloid DCs to induce interferon alpha (IFNα) and
other cytokines and chemokines [21,15]. Imiquimod also
enhances co stimulatory molecule expression important
for triggering an adaptive immune response [15]. Topical
application of the drug has been shown to induce IFNα
and interleukin 6 (IL6) in AK lesions and external genital
warts [22,23]. Imiquimod and the chemically related
immune response modifier resiquimod have also shown
potent vaccine adjuvant effects in mice and man [23-27].
Even though the immune-modulatory activity of imiqui-
mod is well established, the precise molecular changes
responsible for the antilesional activity of topically
applied imiquimod in AK is not fully understood.
The objective of this study was to explore the molecular
processes responsible for the antilesional activity of imiq-
uimod in subjects with actinic keratosis using global gene
expression profiling.
Methods and Materials
Institutional review board/informed consent
This study was conducted at Loma Linda University
School of Medicine/Medical Center, Department of Inter-
nal Medicine, Division of Dermatology, Loma Linda, Cal-
ifornia. The study protocol, subject informed consent
documents, and subject information documents were
submitted to and received approval from the study
center's Institution Review Board. This study was con-
ducted according to the Code of Federal Regulations of
the United States Food and Drug Administration (21 CFR
Part 56, Institutional Review Boards, and Part 50, Protec-
tion of Human Subjects) and the International Confer-
ence on Harmonization Edition 6, Guideline for Good
Clinical Practice.
Study Conduct
This was a phase II, double-blind, placebo-controlled,
randomized parallel group study. Randomized subjects
had at least 5 clinically visible AK lesions within a 25-cm2
area on the balding scalp. Subjects were randomized to
imiquimod or placebo cream in a 3:1 ratio and applied
study cream to the treatment area 3 times per week for 4
weeks. Study cream was applied prior to normal sleeping
hours and remained on the skin for approximately 8
hours before it was removed. Safety evaluations were
made at all treatment and post treatment visits, and
included monitoring of adverse events and local skin reac-
tions, as well as photographing the treatment area and
reviewing any concomitant medications.
At the screening visit, AK lesions were assessed clinically
and by confocal microscopy and a representative lesion
confirmed by histology. Because AK lesions are in general
small in size, histology and gene expression analysis could
not be performed on the same biopsy. Therefore, confocal
microscopy was performed to establish a correlation of
the confocal images and their respective non-sun exposed
non-lesional skin, sun exposed non-lesional skin, actinic
keratoses lesions, and squamous cell carcinoma. All sub-
jects with lesions histologically identified as having a
degree of dysplesia suggestive of squamous cell carcinoma
were disqualified from the study. All sites identified as AK
lesions were marked and a plastic template of their loca-
tions made for exact identification at a later time. Thereaf-
ter, changes in AK lesions due to treatment withJournal of Translational Medicine 2007, 5:7 http://www.translational-medicine.com/content/5/1/7
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imiquimod were assessed clinically and by confocal
microscopy. Lesions were scored as cleared if the skin
exhibited normal epidermis as assessed clinically and by
confocal microscopy. Assessment of lesion regression and
the results of the confocal microscopy as they relate to
aberrant gene expression in AK are discussed in a manu-
script submitted for publication (Torres et al, 2006. Micro
Array Analysis of Aberrant Gene Expression in Actinic
Keratosis: Effect of Imiquimod 5% Cream).
At the treatment initiation visit, a shave biopsy was taken
for gene expression analysis from an untreated AK lesion,
from a sun-exposed non-lesional site on the head and
from a non-lesional sun-unexposed site from under the
arm area. An additional biopsy was taken at each subse-
quent study visit, (treatment period weeks 1, 2, and 4) and
at 4 weeks post treatment of either a remaining AK, or if
no AKs were present, of nonlesional skin at a previously
identified lesional site. Thus each biopsy was of a different
AK lesion. In an effort to standardize the amount of tissue
that was removed at each biopsy, the same size punch was
used to score the skin surrounding all the lesions to be
biopsied for gene expression studies with an attempt to
shave-biopsy the lesion at the papillary dermis level. Biop-
sies were taken 8 hr to 16 hr after the third treatment of
the treatment period. The nonlesional, sun-unexposed
site biopsy was used to establish a baseline for compari-
son of gene expression changes in AK before and after
treatment with imiquimod. Shave biopsies were immedi-
ately immersed in RNALater (Ambion, Austin, Texas),
equilibrated at room temperature for 1 hour, kept at 4°C
for 24 hours, and then stored at -20°C prior to RNA
extraction.
RNA extraction and purification
Total RNA from the biopsy samples was extracted and
purified using Qiagen RNeasy Mini Kit Protocol for the
Isolation of Total RNA from Heart, Muscle and Skin Tissue
(Qiagen, Valencia, California) according to manufac-
turer's instructions. RNA yield varied from 1.5 to 14 υg.
The purity of the RNA was determined by the 260 nm/280
nm absorbance ratio. The median 260 nm/280 nm ratio
value for the 119 samples was 2.0 (range 1.9 to 2.2). RNA
integrity was determined using the Agilent 2100 Bioana-
lyzer and the RNA 6000 Nano Assay (Agilant Technolo-
gies, Palo Alto, CA). All samples gave 28S/18S ratio
between 2 and 3 indicating good quality RNA.
Micro array analysis
Samples for micro array analysis were prepared by 2
rounds of linear target amplification according to the
Affymetrix instructions for eukaryotic small sample prep-
aration [28,29]. Briefly, double-stranded cDNA was syn-
thesized from 100 ng of total RNA with oligo(dT)24T7
primer (Affymetrix, Santa Clara, California), followed by
2 cycles of in vitro transcription of cRNA. The first cycle of
invitro transcription was performed using a T7 polymerase
(MEGAscript T7 Kit, Ambion, Austin, Texas) and the sec-
ond cycle using Enzo BioArray High Yield RNA Transcript
Labeling Kit (Affymetrix). The median value for the bioti-
nylated cRNA yield over the 119 samples was 90 (range 42
to 121). The biotinylated cRNA was hybridized to Affyme-
trix U133A and U133B GeneChip arrays containing
22,253 probes sets each. Each array was hybridized for 16
hours, washed, then stained with streptavidin-phyco-
erythrin conjugate and scanned according to manufac-
turer's instructions. Images were analyzed using Micro
Array Suite Version 5 (MAS5). Chips were normalized to
a global average intensity of 150 to allow chip-to-chip
comparison. The quality of the images was ascertained by
monitoring the noise, background, percent transcript
present, and the 3'/5' ratio for the housekeeping gene glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) which
ranged from 1.5 to 5 and beta actin which ranged from 7
to 24. These values are similar to those reported for dou-
ble amplification protocols [29,30].
TaqMan™ real time reverse transcriptase polymerase 
chain reaction
TaqMan real time RT-PCR was performed for a number of
the genes to confirm the micro array results. cDNA was
reverse transcribed from total RNA using Invitrogen
Superscript First-Strand Synthesis System for RT-PCR (Inv-
itrogen, Carlsbad, California). Real time RT-PCR was per-
formed using the Applied Biosystems 7900HT™ sequence
detection instrument (Applied Biosystems, Foster City,
California), and TaqMan low density custom array micro
fluidic cards (Applied Biosystems, Foster City, California)
as described previously[31]. The micro fluidic cards con-
sisted of 8 ports with 24 different TaqMan primer pair/
probe sets arrayed in duplicate in a 384-well micro plate
footprint. Each well contained a gene-specific forward and
reverse primer, as well as a gene-specific probe, which is
labeled at the 5' position with 6FAM (areporter dye) and
at the 3' position with minor groove binder/non-fluores-
cent quencher. Samples were mixed with TaqMan Univer-
sal PCR Master Mix (Applied Biosystems, Foster City,
California), applied to each port of the card, and analyzed
by PCR on the 7900HT instrument using Applied Biosys-
tems Sequence Detection System 2.0 software according
to the manufacturer's instructions. A total of 46 selected
genes associated with the Toll-like receptor pathway,
apoptosis, cell cycle, and immune cell infiltration were
analyzed using the TaqMan arrays. The housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used to normalize each sample. The TLR
copy number was calculated for 2 ng of RNA.Journal of Translational Medicine 2007, 5:7 http://www.translational-medicine.com/content/5/1/7
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Analysis of affymetrix gene chip data
Signals from the gene chip images of biopsy samples for
untreated normal skin obtained from sun-unexposed sites
were used as a control for the calculation of changes in
expression in samples of pretreatment AK lesions and AK
lesions during and after treatment (treatment weeks 1, 2,
and 4 and 4 weeks post treatment). The statistical algo-
rithm in MAS5 evaluates the image for the expression sig-
nal, the absent/present call, and the p-value associated
with the signal. It also evaluates the fold change of the
sample relative to the designated control sample
expressed as the signal log2 ratio, the p-value associated
with the fold change, and the direction of change
(increased, I; decreased, D; or no call, NC). Using the
Affymetrix data mining tool software, the expression data
from MAS5 were filtered on the basis of specific criteria to
identify differentially expressed genes. A given gene was
retained if 1sample from the series passed the following
criteria: signal detection p-value ≤ 0.01, signal log2 ratio ≤
-2 or ≥ 2, and a change call designation of 'increased' (I)
or 'decreased' (D). A total of 1682 genes passed these cri-
teria.
There was a large subject-to-subject variation in the mag-
nitude of changes in expression, as well as the temporal
pattern of expression (subject-specific variation in magni-
tude of response with treatment time) of the 1682 genes.
This variation is exemplified in Figure 1, which shows the
variation in the temporal expression of IRF7 for selected
subjects. Peak expression varied from week 1-treatment to
week 4-treatment depending on the subject. This variation
may be due to the inherent differences in the responses of
subjects and (or) due to variation in the time from treat-
ment to biopsy (range 8 to 16 hr). In order to identify dif-
ferentially expressed genes in the treatment group without
regard to variation in temporal response, the data were
reduced in the following manner. The fold change values
for samples in the week 1, week 2 and week 4 treatment
groups for the 1682 genes for each subject were compared
to identify the maximum change in expression (increased
or decreased) due to imiquimod or placebo treatment.
This value was designated as the treatment-response fold
change for imiquimod or placebo and used in the ANOVA
described in the Statistical Analysis section.
Variation in the temporal expression of IRF7 during treatment with imiquimod as determined by real time RT-PCR Figure 1
Variation in the temporal expression of IRF7 during treatment with imiquimod as determined by real time RT-PCR. 'AK,' des-
ignates pretreatment AK lesions. 'WK1 IMIQ', 'WK2 IMIQ' and 'WK4 IMIQ' designate treatment times week 1, 2 and 4. '4 WK 
Post designates' 4 weeks post end of treatment (WK4 treatment). Fold change was calculated with respect to sun-unexposed, 
non-lesional skin. S-01, S-02, S-06, S-15 and S-16 are samples from subjects 1, 2, 6, 15 and 16.
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Cluster analysis was performed with Spotfire Decision-
Site-8.1 for Functional Genomics (Spotfire Inc, Somer-
ville, Massachusetts), using the Unweighted Pair-Group
Method with Arithmetic mean (UPGMA) and the Eucli-
dean similarity measure. Functional categorization of
genes was based on gene ontology analysis using the
Ontology Browser in Spotfire and gene descriptions at the
National Center for Biotechnology Information (NCBI)
website [32]. The ontology browser calculates a Fisher's
Exact Test p-value, which reflects the chance that the gene
ontology category is represented by random chance [33].
P-value < 0.05 is considered significant.
Statistical analysis
The natural log of the fold change (with respect to sun-
unexposed normal skin) from the Affymetrix gene expres-
sion and the real time RT-PCR experiments were used in
an ANOVA to determine statistically significant changes
in expression between sample groups. Due to the small
sample size of the vehicle group, 4 subjects, compared to
13 subjects in the imiquimod-treated group, a one way
ANOVA comparing vehicle-treated subjects to imiqui-
mod-treated subjects is not expected to yield a reliable
determination of imiquimod-response genes. Therefore, a
2-way ANOVA using a blocking factor to account for
repeat observations on the same subject was used to com-
pare: (1) the fold change for pretreatment AK (n = 13) and
the fold change during treatment with imiquimod (n =
13), and (2) the fold change for pretreatment AK (n = 13)
and the fold change for samples taken 4 weeks after the
last imiquimod treatment (n = 13). The 'during treatment'
fold change is the maximum response fold change value
(decreased or increased) selected from week 1, week 2 and
week 4 treatment fold changes. Differences between sam-
ple groups were considered significant if the p-value for
the ANOVA was < 0.05.
Results and Discussion
Demographics and response to treatment
Seventeen white males were randomized to receive treat-
ment (13 to imiquimod and 4 to placebo). The mean age
was 75 years (range, 62 to 89 years). All 17 subjects in the
study completed the treatment and post treatment por-
tions of the study. The median number of AK lesions at
baseline was 10 per subject (range, 6 to 13 lesions).
Because of the short duration of the follow-up period (4
weeks for the post treatment period), efficacy was not
measured in this study. However, clinical clearance was
observed in 25% of the imiquimod-treated subjects 4
weeks after the end of treatment. Imiquimod-treated sub-
jects 1, 2, 4, and 6 and placebo-treated subject 7 were
assessed as having clinical clearance of lesions 4 weeks
post treatment as determined by return of the lesional site
to normal skin. The complete clearance rate in a study
where AK subjects were treated for 16 weeks, with a post
treatment period of 8 weeks, was 57% [17].
Analysis of global gene expression using Affymetix 
GeneChips: Gene Ontology classification
A 2-way analysis of variance (ANOVA) was performed
comparing the treatment response gene expression fold
change (the maximum response value from week 1, week
2 and week 4 treatments) of samples from the imiqui-
mod-treated subjects to the gene expression fold change
values of their respective pretreatment AK samples. This
comparison resulted in 530 unique genes that had p-val-
ues < 0.05 and a median fold change from pretreatment
AK <-2 for suppressed genes and >2 for induced genes.
Data for the 530 genes is documented in [Additional file
1]. Two-way ANOVA comparing pretreatment AK samples
and samples taken 4 weeks after the last imiquimod treat-
ment resulted in 111 unique genes that differentiated the
2 groups with a p-value < 0.05 [see Additional file 1]. The
expression of the rest of the genes returned to basal levels
4 weeks post treatment. Of the total number of differen-
tially regulated genes during imiquimod treatment or 4
weeks post treatment, 87% were up-regulated and 13%
were down-regulated.
Table 1 summarizes the gene ontology classification of
imiquimod-modulated genes from the Affymetrix analy-
sis. P-values for representation of ontology categories are
given for categories with p-values < 0.05. Of the 530
unique genes whose expression was modulated by treat-
ment, 436 genes had some annotation in the ontology
database. Of these, 106 were annotated to the immune
response category, 123 to signal transduction, 72 to recep-
tor activity, and 25 to inflammatory response. Specific
genes in several molecular function categories are also
listed. Other ontology categories that were represented in
the data but had p-values >0.05 for representation in the
gene ontology category included metabolism (148 genes),
development (37 genes) and regulation of transcription
(24 genes). The ontology analysis shows that imiquimod
treatment of AK results in global gene expression changes
impacting various cellular processes, with immune
response and signal transduction being the 2 major proc-
esses represented.
Validation of selected genes observed in the Affymetrix 
experiment using real time reverse transcriptase 
polymerase chain reaction
Micro array analysis may not be sensitive enough to cap-
ture all changes in gene expression. In comparison, real
time reverse transcriptase polymerase chain reaction (RT-
PCR) has been shown to be more sensitive for the detec-
tion of low abundance transcripts [31]. Therefore, we ana-
lyzed AK samples and imiquimod treated AK samples for
a selected set of genes using real time RT-PCR. The data isJournal of Translational Medicine 2007, 5:7 http://www.translational-medicine.com/content/5/1/7
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Table 1: Gene Ontology Classification of Imiquimod-Induced Genes in AK Lesions
Ontology Genes in 
the Data1
Annotated 
Genes2
P-value3 Increased 
Expression
Decreased 
Expression
Description of Processes and Specific 
Genes
Total 436 17479 369 67
Response to stimuli 137 2475 2.13E-19 125 12 defense response, response to external biotic 
stimuli including, pest and pathogens, 
antimicrobial, anti-fungal, anti-viral response
Defense response 105 1174 1.54E-40 102 3 immune response, inflammatory response
Immune response 106 1020 3.05E-40 104 2 cellular defense response, humoral defense 
response, antigen binding, pattern binding, 
cytokine synthesis, chemokine synthesis, 
antigen presentation processing, inflammatory 
response
Response to stress 68 1337 1.77E-12 63 5 response to pest and pathogen, inflammatory 
response, response to virus, response to 
wounding
Inflammatory response 25 244 4.35E-11 25 0 defensive reaction (by vertebrate tissue) to 
infection or injury
Response to wounding 39 395 3.72E-16 39 0 defensive reaction (by vertebrate tissue) to 
physical injury
Signal transduction 123 3547 4.70E-06 95 17 cytokine signaling, death receptor signaling, G-
protein coupled receptor signaling, intigrin 
binding, MHC protein binding
Receptor activity 72 1914 1.80E-07 62 10 chemokine receptors, pattern recognition 
receptors, immunoglobulin receptors, 
complement receptors, MHC I\MHCII 
receptors, scavenger receptors, 
Hematopoietin/interferon class (D200) 
receptors
Antigen binding 8 91 2.66E-03 8 0 SCF1, IGLV2-14, LAG3, LILRA1, SLAMF1, TRA@, 
TRGC2, TAP2
Carbohydrate binding 16 326 1.18E-03 14 2 CCL8, CD69, CLEC4A, FCN1, FGFR2, GALNT7, 
HMMR, KLRC1/KLRC2, KLRF1, LGALS2, LGALS9, 
POSTN, PTN, SELL, SELPLG, SN
Pattern binding 10 159 4.58E-02 8 2 CCL8, CD14, FGFR2, HMMR, POSTN, PTN, 
TLR2, TLR7, TLR8, TLR4
Cytokine receptors 9 99 1.97E-04 9 0 CCR5, CCR1, CD74, CSF2RB, CXCR4, IL10RA, 
IL1RL1, IL21R, TNFRSF1B
Cytokines 12 257 1.11E-04 11 1 CCL3, CCL5, CCL8, CXCL5, CXCL10, CXCL11, 
CXCL12, CXCL16, TNFSF10, ECGF1, PTN, 
SLURP1
Immunoglobulin 
binding
4 25 1.56E-03 4 0 FCER1A, FCER1G, FCGR3B, 214511_x_at
Cystein type 
endopeptidase
9 169 8.21E-03 9 0 CASP1, CASP8, CTSB, CTSL, CTSC, STSS, LGMN, 
TNFAIP3, USP18
1Number of genes in the data for which annotation was found in the Gene Ontology database.
2Total number of gene with annotation in the Gene Ontology database.
3P-value for representation of gene ontology category in the data.Journal of Translational Medicine 2007, 5:7 http://www.translational-medicine.com/content/5/1/7
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summarized in [Additional File 2] which compares the
median fold change values (13 imiquimod-treated sub-
jects) measured using both Affymetrix GeneChip analysis
and RT-PCR for a subset of the genes. In general, good
agreement was obtained between the 2 methods, with the
RT-PCR data showing similar or higher expression than
the Affymetrix data. Figure 2 shows a comparison of the 2
methods for the expression of interferon regulatory factor
7 (IRF7). The individual fold change values for the 13 imi-
quimod-treated subjects during imiquimod treatment
were used for the regression analysis (R Square = 0.83). In
general, the direction of change in expression for each
gene was the same in both assays whereas the magnitude
of the fold change values was higher for the RT-PCR anal-
ysis than the Affymetrix analysis. Of the 46 genes evalu-
ated on both gene expression platforms, only 3 genes
(CD80, MyD88 and TLR6) were identified as having
changed in expression in the RT-PCR experiments only (p
value ANOVA analysis < 0.05). We did not identify any
genes that were differentially expressed by the Affymetrix
method that were not also differentially expressed by real
time RT-PCR. Thus, overall good agreement was obtained
between the 2 methods, with differences between the 2
methods likely due to the increased sensitivity and quan-
titative nature of the RT-PCR platform.
Imiquimod increases expression of pattern-recognition 
receptors of the innate immune system
Since imiquimod is a TLR7 agonist, we sought to deter-
mine if TLR7 and other TLRs were expressed in AK lesions
and if treatment with imiquimod altered their expression.
We analyzed expression levels of various TLRs in biopsy
samples of pretreatment AK and after treatment with imi-
quimod using RT-PCR. We also measured the expression
levels of MyD88, an adaptor molecule for various TLRs
including TLR7; and IRF7, a transcription factor recently
shown to be important in the regulation of interferon
gene expression through the TLR7 pathway [34]. Figure 3
shows the median expression levels of the various TLRs,
MyD88 and IRF7 for subjects treated with imiquimod (n
= 13) during treatment and 4 weeks post treatment. The
expression of TLR1,  TLR3,  TLR6,  TLR7,  TLR8,  TLR9,
MyD88 and IRF7 were all increased at statistically signifi-
cant levels (p-value < 0.05, during treatment [see also
Additional File 2]. The increase in TLR4 expression did
not reach a statistically significant level (p-value = 0.066)
in the imiquimod-treated samples, whereas the Affyme-
trix data shows a statistically significant increase (p-value
of 0.028). The most statistically significant changes
observed upon treatment with imiquimod were for TLR3,
TLR7, TLR8, and IRF7, with good agreement between the
Affymetrix and RT-PCR analysis both for the magnitude of
change and for the p-values. There was no change in the
expression levels of TLR5 and TLR10 upon treatment with
imiquimod. The data are consistent with previous reports
of induction of TLRs by various TLR agonists and IFNα
[35-37][38,39]. The increased expression of the TLRs may
be a result of increased expression of the genes in cells res-
ident in the skin (e.g., DCs, macrophages) or due to the
influx of cells with high expression of these genes (e.g.,
DCs, macrophages, plasmacytoid DCs). The increased
expression of TLR3, TLR7, and TLR8 is consistent with
increased expression observed in human peripheral blood
mononuclear cells upon treatment with imiquimod. The
data are also consistent with increased expression of TLR7
observed in imiquimod-treated AK [22]. In summary,
treatment of AK lesions with imiquimod results in
increased expression of several TLRs and TLR pathway
components, thus potentially priming for further amplifi-
cation of the innate immune system. The increase in the
expression of IRF7 is also predicted to amplify the innate
immune response by increased expression of type 1 inter-
ferons and interferon-inducible genes.
In addition to the various TLR(s) which recognize viral
and bacterial components, an intracellular antiviral path-
way which detects viral RNA and results in the induction
of type1 interferons has recently been described [40-42].
The central components of this pathway, which are also
inducible by type1 interferons [43,44] are DDX58 (RIG-I,
retinoid acid inducible gene) and IFIH1  (MDA5,
Comparison of gene expression data obtained by Affymetrix  GeneChip analysis and real time RT-PCR Figure 2
Comparison of gene expression data obtained by Affymetrix 
GeneChip analysis and real time RT-PCR. Linear regression 
analysis for IRF7 comparing fold change values for individual 
subjects as measured by Affymetrix analysis and real time 
RT-PCR analysis. The imiquimod response fold change, which 
is the maximum response from week 1, week 2 and week 4 
treatment times was used. Fold change was calculated rela-
tive to sun-unexposed, nonlesional skin samples for 13 sub-
jects treated with imiquimod. The R square value for the 
comparison was 0.83.
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melanoma differentiation antigen 5). Both genes contain
helicase domains responsible for detection of double-
stranded RNA. They also contain caspase recruitment
domains (CARDdomains), which are responsible for sig-
naling through TBK1 (resulting in activation of NFKB and
IRF3), as well as induction of type-1 interferons. The acti-
vation of this pathway leads to growth inhibition as well
as antiviral activity [45]. Figure 4a and 4b show changes in
expression of DDX58 and IFIH1 upon treatment with imi-
quimod as determined from Affymetrix GeneChip analy-
sis. The expression of both genes was increased to
statistically significant levels during treatment. The expres-
sion of DDX58  remained higher than its pretreatment
level (p-value = 0.004), four weeks, post treatment,
whereas that of IFIH1 returned to basal level. The induc-
tion of several members of the cytoplasmic helicase innate
immune pathway, as well as several TLRs, indicates that in
addition to activation of the TLR7 pathway, treatment
with imiquimod also results in priming of other innate
pathways. These pathways may augment other aspects of
the innate immune response and may be important for
eliminating pre-neoplastic cells.
Imiquimod induces a large number of type I interferon-
inducible genes with growth inhibitory and immune-
stimulatory activity
Imidazoquinoline TLR7 agonists such as imiquimod and
resiquimod are know to induce various cytokines, includ-
ing interferon-α, IL6, MCP-1 and IL12 as well as the co-
stimulatory markers CD80 and CD86 [15,46]. Type I
interferons are known to be powerful regulators of the
innate and adaptive immune system through the induc-
tion of various genes with antiviral, anti-tumor and
immune regulatory functions [43,44,47-51]. In this study,
we did not detect increased expression of interferon upon
treatment with imiquimod, but observed the increased
expression of a large number of IFN-inducible genes (114
genes), [see Additional file 3]. The lack of detection of
Basal TLR, IRF7, and MyD88 gene expression in skin biopsies as determined by real time RT-PCR Figure 3
Basal TLR, IRF7, and MyD88 gene expression in skin biopsies as determined by real time RT-PCR. White bars represent pre-
treatment AK, black bars represent during imiquimod treatment (maximum response value from week 1, week 2 and week 4 
treatment times), and hatched bars represent 4-weeks post treatment. Relative copy number was determined as outlined in 
Methods and Materials section. Asterisks indicate those genes that had p-values < 0.05 in the ANOVA, comparing expression 
in pretreatment AK samples to the maximum response expression in samples from subjects (n = 13) during imiquimod treat-
ment. [See Additional file 2].
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type 1 interferons after imiquimod treatment in this study
may be due to the early induction and degradation of
their respective mRNA. Biopsies were taken approxi-
mately 8 to 16 hr after application of the drug. We have
observed that mRNA for type 1 interferons in human
blood mononuclear cells treated with imiquimod peaks
in 1 to 2 hours and declines to basal levels 6 to 8 hours
post treatment (unpublished internal data).
Analysis of gene ontology classification of the interferon-
inducible genes increased by treatment with imiquimod
identified 46 genes with immune response classification.
Figure 5 shows a 2-way hierarchical clustering of the log2
transformed fold changes of all of the 530 imiquimod-
induced genes [see Additional file 1]. Figure 6 exhibits
clustering of the 46 interferon-inducible genes which clas-
sify as immune response genes Two main clusters are
apparent in Figure 5. One cluster consists of 8 imiquimod-
treated samples. The second and larger cluster consists of
all of the pretreatment AK samples, the vehicle-treated
samples (designated as placebo in the figure) and five of
the imiquimod-treated samples for subjects 02, 05, 09, 12
and 17 (IMIQ-02, IMIQ-05, IMIQ-09, IMIQ-12 and
IMIQ-17). The fact that the vehicle-treated samples cluster
with pretreatment AK lesions indicates the lack of a signif-
icant vehicle-effect in the gene expression profile. In Fig-
ure 6, 10 of the imiquimod-treated samples appear in 1
cluster, with IMIQ-02 and IMIQ-05 now as part of the
IMIQ-treated cluster. This cluster is characterized by high
expression of the interferon-inducible genes such as MX1,
IFIT1 and IFIT3. The cluster also contains the samples pla-
cebo-03 and AK-11, indicating that these AK lesions were
already manifesting spontaneous immune response. The
imiquimod-treated samples 09, 12, and 17 are clustered
with the pretreatment AK samples in both figures, indicat-
ing that Subjects 09, 12, and 17 had little gene expression
response to imiquimod. Thus, the 46 interferon-inducible
immune response genes segregate the imiquimod-treated
samples from pretreatment AK and placebo-treated sam-
ples better than the whole set of 530 genes. This group of
genes may therefore be good predictors of gene expression
response to imiquimod. Collectively, these genes have
been reported as 'interferon-signature' genes induced by
several IFNα subtypes and IFNβ in monocytes [51].
Heterogeneity of pretreatment AK lesions was not docu-
mented by clinical assessment in this study. However, the
gene expression profiles shown in Figure 5 and Figure 6
indicate heterogeneity in lesions. In addition to AK 11 and
Placebo 03 in Figure 6 which cluster with the imiquimod
treatment group indicating some level of immune
response in these samples, other AK lesions also show low
levels of expression of interferon inducible genes. For
example, AK 06, AK 03, and AK 07 show low levels of
Increase in expression of the helicase family of virus-sensing genes upon treatment with imiquimod as determined by Affyme- trix GeneChip analysis Figure 4
Increase in expression of the helicase family of virus-sensing genes upon treatment with imiquimod as determined by Affyme-
trix GeneChip analysis. (A)DDX58 (RIG-I) and (B)IFIH1 (MDA5). Experimental conditions are as described in the Methods and 
Materials section. Box plots were generated using MINITAB version 14. 'AK,' 'IMIQ,' and 'Post' designate pretreatment AK, 
imiquimod-treated skin during treatment (maximum response from week 1, week 2 and week 4), and imiquimod-treated skin 4 
weeks post treatment, respectively. Fold change was calculated with respect to sun-unexposed skin. Boxes indicate the median 
95% confidence intervals, asterisks designate outliers, and the lines connect median values. P values are given for 2-way 
ANOVA, comparing the fold change values for pretreatment AK samples and imiquimod-treated samples (n = 13).
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expression of several interferon-inducible genes whereas
AK 16, AK 17, AK 12 and AK 15 show normal to slightly
depressed levels (Figure 6).
Interferon-inducible genes regulate diverse cellular proc-
esses, such as cell growth and differentiation, cell death,
and T-cell co stimulation, activation, and migration.
These genes have been reported to possess antiviral [52-
54], pro-apoptotic [55-57], and anti-proliferative activi-
ties [58,59]. The interferon-inducible genes which
increased following imiquimod treatment include those
known to be induced by viruses as well as those with
known anti-viral activity. These include the 2'5'-oligoade-
nylate synthetases OAS1,  OAS2,  OAS3  and  OASL, the
genes encoding the interferon-inducible proteins with
tetratricopepetide repeats, IFIT1, IFIT2, and IFIT3, IFTM1,
and other interferon inducible genes such as IFI35, IFI16,
MX1, MX2, EIF2AK2 (PRKR), G1P2 (ISG15), G1P3, ISG20,
RSAD2  (Cig5),  CCL8 (MCP2),  CXCL10 (IP10) and
CXCL11 (ITAC) [43,44,47,49-52,54,60,61]. Several of the
interferon-inducible genes were also increased at statisti-
cally significant levels 4 weeks post treatment. These
Cluster analysis of genes regulated by imiquimod treatment Figure 5
Cluster analysis of genes regulated by imiquimod treatment. Two-way hierarchical clustering was performed as described in 
the Methods and Materials section. 'AK,' 'IMIQ,' and 'Placebo' designate the fold change with respect to sun-unexposed, nonle-
sional skin for pretreatment AK samples; for samples during imiquimod treatment (maximum response from week 1, week 2 
and week 4), and samples for vehicle-treatment (maximum response from week 1, week 2 and week 4) respectively. Numbers 
designate subjects. Hierarchical clustering was performed using the Unweighted Pair-Group Method with Arithmetic mean 
(UPGMA) and the Euclidean similarity measure. Red, white, and green indicate up-regulated, unchanged, and down-regulated 
genes, respectively. The color bar insert shows the corresponding expression levels. The cluster consists of 530 imiquimod-
responsive genes whose expression was statistically different when comparing the AK group of samples to the IMIQ group of 
samples. Expression changes for the 530 genes are documented in [Additional file 1].
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included: IRF7, IFI44, IFIT2, IFIT3, IFITM1, IFI35, RSAD2
(Cig5), G1P2, MX1, OAS1, and OAS2 [see Additional file
1].
In addition to interferon-inducible genes with antiviral
activity, several genes known or predicted to possess
growth-inhibition and/or cell-differentiating activities
[49,50] were induced by imiquimod, including IFI16,
AIM2 [62,63], IFIH1 (melanoma differentiation antigen,
MDA5) [45], CXCL10 (IP10) [58] and EIF2AK2 (PRKR)
[64]. Some of the interferon-inducible genes also possess
pro-apoptotic activity, including MX1, TNFSF10 (TRAIL),
OAS1, and PRF1 [55,57,65]. Figure 7a and Figure 7b show
changes in the expression of the pro-apoptotic genes
TNFSF10 (TRAIL) and MX1 with imiquimod treatment as
determined from the Affymetrix analysis. The expression
of MX1 remained elevated at statistically significant level
4 weeks post treatment, whereas the expression of
TNFSF10 returned to basal levels. The data are consistent
with the observation of increased expression of IFNα-
inducible genes in imiquimod-treated BCC and cutane-
ous T-cell lymphoma (CTCL) [66,67]. Thus, interferon-
inducible genes with pro-apoptotic activity (e.g., MX1,
TNFSF10) and growth inhibitory activity (e.g., IFIH1,
AIM2, IFI16) may result in growth inhibition of neoplas-
tic cells whereas those with immune-stimulatory activity
such as CXCL10 (IP10), CXCL11 (ITAC), and CCL8
(MCP2) may facilitate cell-mediated lesion destruction by
recruiting immune cells into the lesions. Indeed, further
evidence for the recruitment of immune cells into AK
lesions with imiquimod treatment is presented in the fol-
lowing sections.
Cluster of 46 immune response genes that are also known to be inducible upon treatment with type 1 interferons as reported  in [18, 43, 45, 48, 51, 102] Cluster analysis was performed as described in Figure 5 Figure 6
Cluster of 46 immune response genes that are also known to be inducible upon treatment with type 1 interferons as reported 
in [18, 43, 45, 48, 51, 102] Cluster analysis was performed as described in Figure 5. [See Additional file 3].
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Imiquimod induces the expression of chemokines 
responsible for recruitment of immune cells to AK lesions
Gene ontology classification (Table 1) shows that 106
genes classified as immune responsive were induced by
imiquimod, some of which are also shown to be inter-
feron α/β-inducible [see Additional File 3]. Out of the 106
immune response genes, several were classified as
cytokines/chemokines and chemokine receptors. In addi-
tion to CXCL10, CXCL11 and CCL8 mentioned above,
other chemokines were induced by imiquimod treatment,
including CCL3 (MIP1a), CCL4 (MIP1b), CCL5 (Rantes),
CXCL12 (SDF1), and CXCL16, and the chemokine recep-
tors CCR1, CCR5, and CXCR4. Figure 8a and 8b illustrate
changes in expression of CXCL10 and CXCL11 observed
upon treatment of AK lesions with imiquimod. The mag-
nitude of the changes observed in the expression of chem-
okine genes during treatment ranged from a median fold
change value of 1.8 for CXCL12  (SDF1) to 40.8 for
CXCL11. The expression of both genes returned to pre-
treatment levels 4 weeks post treatment. These data are
consistent with previous reports of increased expression
of chemokines genes and their receptors upon topical
treatment of BCC and CTCL with imiquimod [67], as well
as  in vitro studies of human blood mononuclear cells
stimulated with other imidazoquinoline TLR7 agonists
showing the induction of CXCL10 and CXCL11 proteins
[46]. The cocktail of chemokines up-regulated by imiqui-
mod is consistent with recruitment and/or activation of
macrophages, DCs, plasmacytoid DCs, gamma/delta T
cells, cytotoxic T cells, and natural killer (NK) cells, and is
also consistent with the cell surface markers indicating the
presence of these cells upon imiquimod treatment.
Indeed, topical treatment of various neoplastic skin con-
ditions with imiquimod cream have shown inflammatory
conditions at the site of treatment, indicating the infiltra-
tion of immune cells into the site [17,19,20,68,69]. In this
study, the gene expression fingerprints that indicate
recruitment of various immune cells are further discussed
below.
Imiquimod increases the expression of genes predictive of 
infiltrating macrophage and dendritic cells
Of the imiquimod-induced genes classified as immune
response in gene ontology, several have receptor activity
and (or) are hematopoietic cell surface markers (Table 1).
The increased expression of these genes indicates the
recruitment of various immune cell types to the lesion
sites. Macrophage and/or monocyte infiltration of AK
lesions upon treatment with imiquimod was indicated by
an increase in CD14, CD163, and CLECSF9 (CLECSF4,
MINCLE), a C-type lectin found on activated macro-
phages [70]. The increase in expression of genes of the
classical complement pathway, C1QA, C1QB, C3AR1, and
C5R1, also indicates an increase in and/or the activation
of macrophages [71]. The data are consistent with histo-
logic observation of macrophage and/or monocyte infil-
tration after application ofimiquimod in the treatment of
AK [72] and in lentigo maligna [73,74].
The presence of DCs is shown by increases in the co stim-
ulatory molecules CD86 and CLEC4A (DCIR, CLECSF6),
as well as by 3 leukocyte immunoglobulin receptors:
Imiquimod treatment is associated with an increase in expression of pro-apoptotic genes as determined by Affymetrix Gene- Chip analysis Figure 7
Imiquimod treatment is associated with an increase in expression of pro-apoptotic genes as determined by Affymetrix Gene-
Chip analysis. (A) TNFSF10 (B)MX1. Experimental conditions and analysis are as described for Figure 4.
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Increase in expression of genes indicating the infiltration of DCs upon treatment with imiquimod as determined by Affymetrix  GeneChip analysis Figure 9
Increase in expression of genes indicating the infiltration of DCs upon treatment with imiquimod as determined by Affymetrix 
GeneChip analysis. (A)CD86 (B) ILT7. Experimental conditions and analysis are as described for Figure 4.
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Increase in expression of chemokines after treatment with imiquimod as determined by Affymetrix GeneChip analysis Figure 8
Increase in expression of chemokines after treatment with imiquimod as determined by Affymetrix GeneChip analysis. 
(A)CXCL10 (IP10), (B)CXCL11 (ITAC). Experimental conditions and analysis are as described for Figure 4.
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LILRB3 (ILT3) and LILRB1 (ILT2) which are expressed in
both myeloid and plasmacytoid DCs [75], while ILT7
(LILRA4,  CD85g) is restricted to plasmacytoid DCs
[76,77]. Figure 9a and Figure 9b illustrate the increase in
expression of CD86 and ILT7 with imiquimod treatment.
The expression of CD86 remained elevated 4 weeks post
treatment. Increased expression is taken as indication of
recruitment of these cells to the site of treatment. These
observations are consistent with previous studies using
topically-applied imiquimod in the treatment of human
BCC [69] and melanoma in mice [78], showing recruit-
ment of plasmacytoid DCs into the site of treatment.
It is interesting to note that CD1C is markedly decreased
upon treatment with imiquimod [see Additional file 3].
CD1c is found on Langerhans cells as well as on DCs
[79,80]. The decrease in CD1C  expression may reflect
(although not exclusively) the migration of CD1C+ Lang-
erhans cells out of the dermis. Migration of Langerhans
cells out of mouse dermis was observed after topical treat-
ment with imiquimod [78,81]. In the case of the Palamara
studies [78] in mouse melanoma, Langerhans cells were
observed to return to normal levels in the dermis by day
20. The decrease in CD1C observed upon treatment of AK
lesions with imiquimod therefore suggests the activation
and migration of Langerhans cells to the lymph nodes and
is consistent with previous observations.
Imiquimod increases the expression of genes predictive of 
infiltrating cytotoxic T cells and natural killer cells
Natural killer cells mediate lysis of tumor cells as well as
virally-infected cells. Natural killer cells preferentially
express several calcium-dependent (C-type) lectins,
known as the NKG2 family, which have been implicated
in the regulation of NK cell function, and are believed to
be important for NK cell-mediated tumor rejection and T-
cell mediated immunity [82]. Transcripts for 3 of these C-
type lectins, KLRC1/C2, KLRK1 (NKG2D) and KLRF1 were
increased in expression in imiquimod-treated samples. In
addition, several genes important to the cytolytic function
of NK cells and cytotoxic T cells, including TYROBP
(DAP12) and CD69  (early T-cell activation antigen),
ITGAL (CD11a), ITGB2 (CD18), ICAM1, and the ligands
for the NKG2 receptors, MICA and MICB [Additional file
1] [83-88] were increased in expression with imiquimod
treatment. Also, genes of the granule products of NK cells
and cytotoxic T cells, such as granzymes GZMA, GZMB,
GZMK, and GYNYL (granulysin, NKG5), PRF (perforin)
and NKG7 (GIG1, GMP-17) were increased in expression,
indicating that these cells are cytolytically active [89-93].
Figure 10a and 10b show changes in the expression of
GZMA and NKG7 after imiquimod treatment. The expres-
sion of both genes returned to pretreatment levels 4 weeks
post treatment. Thus, the coordinate increased expression
of genes important for NK cell recognition of tumor cells,
and for the activation and cytolytic response of NK cells
and cytotoxic T cells, suggests that these cells are at least in
part responsible for the antilesional activity of imiqui-
mod.
Imiquimod increases the expression of genes predictive of 
the activation of the adaptive immune system
The presence of activated T cells in imiquimod-treated AK
lesions is indicated by the expression of several members
Increase in expression of genes associated with NK cells, and cytotoxic T cells after treatment with imiquimod as determined  by Affymetrix gene expression Figure 10
Increase in expression of genes associated with NK cells, and cytotoxic T cells after treatment with imiquimod as determined 
by Affymetrix gene expression. (A)GZMA (B) NKG7. Experimental conditions and analysis are as described for Figure 4.
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of the T-cell activation pathway [Additional File 1]). These
include the T-cell receptor (TCR) subunits TRD and TRG,
TCR-signaling pathway genes such as Fyn, Fyb and LCP2
[94,95], and other genes associated with T-cell activation
such as HCK,  CD69,  PTPRC  (CD45)  SELL  (CD62L, L-
Selectin),  ITGA4  (antigen CD49D, alpha 4 subunit of
VLA-4 receptor), and LAG3. In addition, treatment of AK
lesions with imiquimod resulted in a small but significant
increase in the expression of CD8β, suggesting that there
is an increase in CD8 T cells [96,97]. The presence of CD8
memory T cells in imiquimod-treated subjects is also sug-
gested by increases in expression of SELL, NT5E (CD73),
LGALS2  (galectin 2), and LAIR1  (leukocyte-associated
immunoglobulin-like receptor 1), which was recently
identified to be differentially expressed in mouse memory
Tcells [98]. Figure 11a and Figure 11b illustrate the
increase in expression of SELL and NT5E respectively. The
expression levels of these genes returned to pretreatment
levels 4 weeks post treatment. Taken together, the
increased expression of Tcell receptor genes, T cell activa-
tion marker genes and genes important for T cell co stim-
ulation suggests that treatment with imiquimod results in
the infiltration of T cells into AK lesions. The increased
expression of genes important for the development of T-
cell memory (e.g. SELL, NT5E), as well as genes associated
with cytotoxic T cells (e.g. granzymes and perforin) sug-
gests that imiquimod treatment recruits both memory
and effector T cells. These results are consistent with the
observation of increased CD3, CD4 and CD8 positive
cells after topical application of imiquimod to AK lesions
[72], as well as infiltration of CD8 T cells in BCC [19,66]
and in cutaneous squamous cell carcinoma treated with
topical imiquimod [99]. The increased expression of
genes important in the activation and co stimulation of
cells of the adaptive immune system is consistent with the
infiltration of cells important in the development of the
adaptive immune system. These observations are also
consistent with the reported adjuvant activity of imiqui-
mod and its analog resiquimod [26], and the low recur-
rence rates observed in animal studies [100] and clinical
studies with imiquimod [101]. These same observations
suggest that imiquimod may also prevent recurrence of
AK lesions as well.
In summary, the data suggest that the therapeutic effect of
imiquimod in the treatment of AK involves the stimula-
tion of both the innate and adaptive immune responses.
The role of type 1 interferons in imiquimod's mechanism
of action is underscored by the induction of large num-
bers of IFNα/β-inducible genes with tumor growth-inhib-
itory and immune stimulatory activity. Data indicate that
the antilesional activity of imiquimod is a result of the
induction of a strong immune cell-mediated cytolytic and
apoptotic gene expression program that leads to destruc-
tion of AK lesions and sun-damaged cells. The develop-
ment of immune memory indicated by this study, as well
as the observation of low recurrence in clinical studies,
makes imiquimod a unique therapy for AK as well as for
other cutaneous neoplasms.
Abbreviations
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BCC–basal cell carcinoma, DC–dendritic cells, IFN–inter-
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Increase in expression of genes associated with lymphocyte function after treatment with imiquimod as determined by Affyme-
trix GeneChip analysis. (A) SELL (CD62L) (B) NT5E (DC73). Experimental conditions and analysis are as described for Figure 4.
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